title: Response to letter regarding article, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin".
authors.affiliation: Coagulation Unit, Hematology Center, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.
authors.forename: Ammar
authors.initials: A
authors.lastname: Majeed
authors.affiliation: Department of Medicine, Soonchunhyang University Gumi's Hospital, North Kyungsang Province, South Korea.
authors.forename: Hun-Gyu
authors.initials: HG
authors.lastname: Hwang
authors.affiliation: McMaster University, Population Health Research Institute, Hamilton, ON, Canada.
authors.forename: Stuart J
authors.initials: SJ
authors.lastname: Connolly
authors.affiliation: McMaster University, Population Health Research Institute, Hamilton, ON, Canada.
authors.forename: John W
authors.initials: JW
authors.lastname: Eikelboom
authors.affiliation: Lankenau Medical Center, Thomas Jefferson Medical College, Wynnewood, PA.
authors.forename: Michael D
authors.initials: MD
authors.lastname: Ezekowitz
authors.affiliation: Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
authors.forename: Lars
authors.initials: L
authors.lastname: Wallentin
authors.affiliation: Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, GermanyFaculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany.
authors.forename: Martina
authors.initials: M
authors.lastname: Brueckmann
authors.affiliation: Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany.
authors.forename: Mandy
authors.initials: M
authors.lastname: Fraessdorf
authors.affiliation: McMaster University, Population Health Research Institute, Hamilton, ON, Canada.
authors.forename: Salim
authors.initials: S
authors.lastname: Yusuf
authors.affiliation: Department of Medicine, McMaster University, Hamilton, ON, CanadaKarolinska Institutet, Stockholm, Sweden.
authors.forename: Sam
authors.initials: S
authors.lastname: Schulman
mesh_terms: D001281:Atrial Fibrillation / Q000188:drug therapy*; D001562:Benzimidazoles / Q000009:adverse effects*; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced* / Q000628:therapy*; D006801:Humans; D008297:Male; D054556:Venous Thromboembolism / Q000188:drug therapy*; D014859:Warfarin / Q000009:adverse effects*; D015091:beta-Alanine / Q000031:analogs & derivatives*
chemical_list: D001562:Benzimidazoles; D015091:beta-Alanine; D014859:Warfarin